Author

Tomáš Vaněček

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Dermal Nerve Sheath Myxomas Harbor Recurrent DPYSL2::CDX1 Fusions and Expand the Spectrum of CDX1-Rearranged Soft Tissue Tumors.

Dermal nerve sheath myxoma (DNSM) is a rare benign mesenchymal tumor with presumed nerve sheath differentiation with distinctive morphologic and immunophenotypic features; however, its molecular pathogenesis remains poorly understood. We investigated a series of nine morphologically classic DNSMs and performed molecula...

Carina A. Dehner, L. Warmke, Sion W. Jasmine et al. · Modern Pathology · 0 citations

Open access Sep 2026

Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours.

BACKGROUND GPNMB is a lysosomal transmembrane protein that has emerged as a diagnostic marker for tumours driven by the microphthalmia-associated transcription factor family (TFE3 and TFEB) and mTOR pathway activation. Diffuse, moderate-to-strong GPNMB positivity has been proposed as a surrogate marker for both translo...

Josef Skopal, M. Švajdler, N. Ptáková et al. · Histopathology · 0 citations

Case report Open access Aug 2026

FGFR2 fusion as the key to targeted therapy - a case report with a diagnostic turning point.

Targeted therapy with FGFR tyrosine kinase inhibitors, particularly in the presence of the FGFR3-TACC3 gene fusion, is capable of inducing long-term remission even in advanced disease previously treated with multiple modalities, as evidenced by the observations.

M. Pesek, M. Drosslerová, Tomáš Vaněček et al. · Klinicka onkologie · 0 citations